Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Research Report 2021-2028

Market Overview:

The global hypoactive sexual desire disorder (HSDD) treatment market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of HSDD, rising awareness about available treatments, and growing demand for effective and safe treatments. The global hypoactive sexual desire disorder (HSDD) treatment market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into buspirone, bupropion, testosterone therapy, flibanserin therapy, bremelanotide therapy cognitive behavior therapy (CBT), and others. On the basis of application, the market is segmented into hospitals & clinics and others. The hospitals & clinics segment dominates in terms of revenue share in 2017 owing to high adoption rates for HSDD treatments in this setting across regions.

Product Definition:

Hypoactive sexual desire disorder (HSDD) is a condition characterized by low libido or lack of interest in sex. While there are many potential causes of HSDD, the underlying cause is often unknown. HSDD can cause distress and negatively affect quality of life. Treatment options include lifestyle changes, medications, and therapy.

Buspirone:

Buspirone, also known as 5-HT1A receptor partial agonist is an anti-depressant drug developed originally by Hoffman La Roche Ltd. in the early 1980s. It was never marketed in the U.S., however, due to patent expiration in 2007 it has been made available to consumers through online pharmacies and over-the-counter sales since 2008 without prescription or restrictions.

Bupropion:

Bupropion is an FDA-approved prescription drug used to treat HSDD. It is also used as an off-label treatment for depression, which can cause low sexual desire. Bupropion has been found to be more effective than SSRIs in treating hypoactive sexual desire disorder (HSDD) and has fewer side effects compared to other drugs such as Wellbutrin or Zoloft. The U.S.

Application Insights:

Based on application, the market is segmented into hospitals, clinics and other medical facilities. The others segment includes online/non-medical facilities. In 2017, the hospital segment dominated the global hypoactive sexual desire disorder (HSDD) treatment market owing to factors such as a large patient base and availability of advanced healthcare services in hospitals. However, with growing awareness about HSDD among both patients and healthcare providers coupled with increasing government initiatives to curb this condition, other sexual dysfunction clinics are expected to witness significant growth over the forecast period.

The clinic application is expected to grow at a faster rate than that of hospital based treatment due to factors such as more convenience for patients along with better privacy for them while receiving treatments for HSDD from specialized professionals who understand its complexities along with effective management strategies specific towards treating this condition effectively.

Regional Analysis:

North America dominated the global market in 2017. This can be attributed to the presence of a large number of companies manufacturing and marketing HSDD drugs, high awareness about available treatment options, and availability of well-established healthcare facilities in this region. Moreover, rising cases of sexual dysfunction among menopausal women are expected to fuel growth during the forecast period.

Asia Pacific is estimated to witness lucrative growth over the forecast period owing to increasing prevalence rates for Hypoactive Sexual Desire Disorder (HSDD) coupled with growing target population base especially in India and China. In addition, improving healthcare infrastructure along with rising awareness about available treatment options is anticipated to boost demand for anti-sexual desire drugs in this region during the forecast period from 2018 to 2030 or until effective generic versions become available on commercial markets at that time frame.

Growth Factors:

Increasing awareness about HSDD and its treatment options among people
Growing number of clinical studies on the efficacy of various treatments for HSDD
Launch of new and innovative therapies for treating HSDD
increasing number of women who are seeking help for their low sexual desire
Rising demand from emerging markets

Scope Of The Report
Report Attributes Report Details
Report Title Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Research Report
By Type Buspirone, Bupropion, Testosterone, Flibanserin, Bremelanotide, Cognitive Behavior Therapy, Hypoactive Sexual Desire Disorder (HSDD) Treatmen
By Application Hospitals, Clinic, Others
By Companies AMAG Pharmaceuticals, Allergan, Plc., Ivix LLX, EndoCeutics, Inc., Emotional Brain BV, S1 Biopharma, Inc., Sprout Pharmaceuticals, Inc., Hypoactive Sexual Desire Disorder (HSDD) Treatmen
Regions Covered North America, Europe, APAC, Latin America, MEA
Base Year 2021
Historical Year 2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year 2030
Number of Pages 245
Number of Tables & Figures 172
Customization Available Yes, the report can be customized as per your need.

Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Report Segments:
The global Hypoactive Sexual Desire Disorder (HSDD) Treatment market is segmented on the basis of:
Types
Buspirone, Bupropion, Testosterone, Flibanserin, Bremelanotide, Cognitive Behavior Therapy, Hypoactive Sexual Desire Disorder (HSDD) Treatmen
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinic, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
AMAG PharmaceuticalsAllergan, Plc.Ivix LLXEndoCeutics, Inc.Emotional Brain BVS1 Biopharma, Inc.Sprout Pharmaceuticals, Inc.Hypoactive Sexual Desire Disorder (HSDD) Treatmen

Highlights of The Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Report:
The market structure and projections for the coming years.
Drivers, restraints, opportunities, and current trends of market.
Historical data and forecast.
Estimations for the forecast period 2030.
Developments and trends in the market.
By Type:
Buspirone
Bupropion
Testosterone
Flibanserin
Bremelanotide
Cognitive Behavior Therapy
Hypoactive Sexual Desire Disorder (HSDD) Treatmen
By Application:
Hospitals
Clinic
Others
Market scenario by region, sub-region, and country.
Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Hypoactive Sexual Desire Disorder (HSDD) Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
North America
Europe
Asia Pacific
Middle East & Africa
Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
Correctly Positioning New Products
Market Entry Strategies
Business Expansion Strategies
Consumer Insights
Understanding Competition Scenario
Product & Brand Management
Channel & Customer Management
Identifying Appropriate Advertising Appeals

8 Reasons to Buy This Report
Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
Implemented Robust Methodology to Prepare the Report
Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
Provides Information About the Top-winning Strategies Implemented by Industry Players.
In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
Customization of the Report Available

Frequently Asked Questions?

What is Hypoactive Sexual Desire Disorder (HSDD) Treatment?

HSDD is a mental health disorder that causes a person to have low levels of sexual desire. Treatment for HSDD typically includes counseling and medication.

Who are the major vendors in hypoactive sexual desire disorder (hsdd) treatment market?

Some of the major companies in the hypoactive sexual desire disorder (hsdd) treatment market are AMAG Pharmaceuticals, Allergan, Plc., Ivix LLX, EndoCeutics, Inc., Emotional Brain BV, S1 Biopharma, Inc., Sprout Pharmaceuticals, Inc., Hypoactive Sexual Desire Disorder (HSDD) Treatmen.

                                            
                                               1. Executive Summary

2. Assumptions and Acronyms Used

3. Research Methodology

4. Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Overview
   4.1. Introduction
      4.1.1. Market Taxonomy
      4.1.2. Market Definition
   4.2. Macro-Economic Factors
      4.2.1. Industry Outlook
   4.3. Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Dynamics
      4.3.1. Market Drivers
      4.3.2. Market Restraints
      4.3.3. Opportunity
      4.3.4. Market Trends
   4.4. Hypoactive Sexual Desire Disorder (HSDD) Treatment Market - Supply Chain
   4.5. Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Forecast
      4.5.1. Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size (US$ Mn) and Y-o-Y Growth
      4.5.2. Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size (000 Units) and Y-o-Y Growth
      4.5.3. Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Absolute $ Opportunity

5. Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Analysis and Forecast by Type
   5.1. Market Trends
   5.2. Introduction
      5.2.1. Basis Point Share (BPS) Analysis by Type
      5.2.2. Y-o-Y Growth Projections by Type
   5.3. Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size and Volume Forecast by Type
      5.3.1. Buspirone
      5.3.2. Bupropion
      5.3.3. Testosterone
      5.3.4. Flibanserin
      5.3.5. Bremelanotide
      5.3.6. Cognitive Behavior Therapy
      5.3.7. Hypoactive Sexual Desire Disorder (HSDD) Treatmen
   5.4. Absolute $ Opportunity Assessment by Type
   5.5. Market Attractiveness/Growth Potential Analysis by Type

6. Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Analysis and Forecast by Application
   6.1. Market Trends
   6.2. Introduction
      6.2.1. Basis Point Share (BPS) Analysis by Application
      6.2.2. Y-o-Y Growth Projections by Application
   6.3. Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size and Volume Forecast by Application
      6.3.1. Hospitals
      6.3.2. Clinic
      6.3.3. Others
   6.4. Absolute $ Opportunity Assessment by Application
   6.5. Market Attractiveness/Growth Potential Analysis by Application

7. Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Analysis and Forecast by Sales Channel
   7.1. Market Trends
   7.2. Introduction
      7.2.1. Basis Point Share (BPS) Analysis by Sales Channel 
      7.2.2. Y-o-Y Growth Projections by Sales Channel
   7.3. Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size and Volume Forecast by Sales Channel 
      7.3.1. Manufacturer/Distributor/Service Provider
      7.3.2. Aftermarket
   7.4. Absolute $ Opportunity Assessment by Sales Channel
   7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel

8. Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Analysis and Forecast by Region
   8.1. Market Trends
   8.2. Introduction
      8.2.1. Basis Point Share (BPS) Analysis by Region
      8.2.2. Y-o-Y Growth Projections by Region
   8.3. Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size and Volume Forecast by Region
      8.3.1. North America
      8.3.2. Latin America
      8.3.3. Europe
      8.3.4. Asia Pacific
      8.3.5. Middle East and Africa (MEA)
   8.4. Absolute $ Opportunity Assessment by Region
   8.5. Market Attractiveness/Growth Potential Analysis by Region
   8.6. Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Demand Share Forecast, 2019-2026

9. North America Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Analysis and Forecast
   9.1. Introduction
      9.1.1. Basis Point Share (BPS) Analysis by Country
      9.1.2. Y-o-Y Growth Projections by Country
   9.2. North America Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size and Volume Forecast by Country
      9.2.1. U.S.
      9.2.2. Canada
   9.3. Absolute $ Opportunity Assessment by Country
   9.4. North America Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size and Volume Forecast by Application
      9.4.1. Hospitals
      9.4.2. Clinic
      9.4.3. Others
   9.5. Basis Point Share (BPS) Analysis by Application
   9.6. Y-o-Y Growth Projections by Application
   9.7. North America Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size and Volume Forecast by Type
      9.7.1. Buspirone
      9.7.2. Bupropion
      9.7.3. Testosterone
      9.7.4. Flibanserin
      9.7.5. Bremelanotide
      9.7.6. Cognitive Behavior Therapy
      9.7.7. Hypoactive Sexual Desire Disorder (HSDD) Treatmen
   9.8. Basis Point Share (BPS) Analysis by Type
   9.9. Y-o-Y Growth Projections by Type
   9.10. Market Attractiveness/Growth Potential Analysis
      9.10.1. By Country
      9.10.2. By Product Type
      9.10.3. By Application
      9.10.4. By Sales Channel
   9.11. North America Hypoactive Sexual Desire Disorder (HSDD) Treatment Demand Share Forecast, 2019-2026

10. Latin America Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Analysis and Forecast
   10.1. Introduction
      10.1.1. Basis Point Share (BPS) Analysis by Country
      10.1.2. Y-o-Y Growth Projections by Country
      10.1.3. Latin America Average Pricing Analysis
   10.2. Latin America Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size and Volume Forecast by Country
      10.2.1. Brazil
      10.2.2. Mexico
      10.2.3. Rest of Latin America
   10.3. Absolute $ Opportunity Assessment by Country
   10.4. Latin America Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size and Volume Forecast by Application
      10.4.1. Hospitals
      10.4.2. Clinic
      10.4.3. Others
   10.5. Basis Point Share (BPS) Analysis by Application
   10.6. Y-o-Y Growth Projections by Application
   10.7. Latin America Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size and Volume Forecast by Type
      10.7.1. Buspirone
      10.7.2. Bupropion
      10.7.3. Testosterone
      10.7.4. Flibanserin
      10.7.5. Bremelanotide
      10.7.6. Cognitive Behavior Therapy
      10.7.7. Hypoactive Sexual Desire Disorder (HSDD) Treatmen
   10.8. Basis Point Share (BPS) Analysis by Type
   10.9. Y-o-Y Growth Projections by Type
   10.10. Market Attractiveness/Growth Potential Analysis
      10.10.1. By Country
      10.10.2. By Product Type
      10.10.3. By Application
      10.10.4. By Sales Channel
   10.11. Latin America Hypoactive Sexual Desire Disorder (HSDD) Treatment Demand Share Forecast, 2019-2026

11. Europe Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Analysis and Forecast
   11.1. Introduction
      11.1.1. Basis Point Share (BPS) Analysis by Country
      11.1.2. Y-o-Y Growth Projections by Country
      11.1.3. Europe Average Pricing Analysis
   11.2. Europe Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size and Volume Forecast by Country
      11.2.1. Germany
      11.2.2. France
      11.2.3. Italy
      11.2.4. U.K.
      11.2.5. Spain
      11.2.6. Russia
      11.2.7. Rest of Europe
   11.3. Absolute $ Opportunity Assessment by Country
   11.4. Europe Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size and Volume Forecast by Application
      11.4.1. Hospitals
      11.4.2. Clinic
      11.4.3. Others
   11.5. Basis Point Share (BPS) Analysis by Application
   11.6. Y-o-Y Growth Projections by Application
   11.7. Europe Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size and Volume Forecast by Type
      11.7.1. Buspirone
      11.7.2. Bupropion
      11.7.3. Testosterone
      11.7.4. Flibanserin
      11.7.5. Bremelanotide
      11.7.6. Cognitive Behavior Therapy
      11.7.7. Hypoactive Sexual Desire Disorder (HSDD) Treatmen
   11.8. Basis Point Share (BPS) Analysis by Type
   11.9. Y-o-Y Growth Projections by Type
   11.10. Market Attractiveness/Growth Potential Analysis
      11.10.1. By Country
      11.10.2. By Product Type
      11.10.3. By Application
      11.10.4. By Sales Channel
   11.11. Europe Hypoactive Sexual Desire Disorder (HSDD) Treatment Demand Share, 2019-2026

12. Asia Pacific Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Analysis and Forecast
   12.1. Introduction
      12.1.1. Basis Point Share (BPS) Analysis by Country
      12.1.2. Y-o-Y Growth Projections by Country
      12.1.3. Asia Pacific Average Pricing Analysis
   12.2. Asia Pacific Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size and Volume Forecast by Country
      12.2.1. China
      12.2.2. Japan
      12.2.3. South Korea
      12.2.4. India
      12.2.5. Australia
      12.2.6. Rest of Asia Pacific (APAC)
   12.3. Absolute $ Opportunity Assessment by Country
   12.4. Asia Pacific Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size and Volume Forecast by Application
      12.4.1. Hospitals
      12.4.2. Clinic
      12.4.3. Others
   12.5. Basis Point Share (BPS) Analysis by Application
   12.6. Y-o-Y Growth Projections by Application
   12.7. Asia Pacific Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size and Volume Forecast by Type
      12.7.1. Buspirone
      12.7.2. Bupropion
      12.7.3. Testosterone
      12.7.4. Flibanserin
      12.7.5. Bremelanotide
      12.7.6. Cognitive Behavior Therapy
      12.7.7. Hypoactive Sexual Desire Disorder (HSDD) Treatmen
   12.8. Basis Point Share (BPS) Analysis by Type
   12.9. Y-o-Y Growth Projections by Type
   12.10. Market Attractiveness/Growth Potential Analysis
      12.10.1. By Country
      12.10.2. By Product Type
      12.10.3. By Application
      12.10.4. By Sales Channel
   12.11. Asia Pacific Hypoactive Sexual Desire Disorder (HSDD) Treatment Demand Share, 2019-2026

13. Middle East & Africa Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Analysis and Forecast
   13.1. Introduction
      13.1.1. Basis Point Share (BPS) Analysis by Country
      13.1.2. Y-o-Y Growth Projections by Country
      13.1.3. Asia Pacific Average Pricing Analysis
   13.2. Middle East & Africa Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size and Volume Forecast by Country
      13.2.1. Saudi Arabia
      13.2.2. South Africa
      13.2.3. UAE
      13.2.4. Rest of Middle East & Africa (MEA)
   13.3. Absolute $ Opportunity Assessment by Country
   13.4. Middle East & Africa Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size and Volume Forecast by Application
      13.4.1. Hospitals
      13.4.2. Clinic
      13.4.3. Others
   13.5. Basis Point Share (BPS) Analysis by Application
   13.6. Y-o-Y Growth Projections by Application
   13.7. Middle East & Africa Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Size and Volume Forecast by Type
      13.7.1. Buspirone
      13.7.2. Bupropion
      13.7.3. Testosterone
      13.7.4. Flibanserin
      13.7.5. Bremelanotide
      13.7.6. Cognitive Behavior Therapy
      13.7.7. Hypoactive Sexual Desire Disorder (HSDD) Treatmen
   13.8. Basis Point Share (BPS) Analysis by Type
   13.9. Y-o-Y Growth Projections by Type
   13.10. Market Attractiveness/Growth Potential Analysis
      13.10.1. By Country
      13.10.2. By Product Type
      13.10.3. By Application
      13.10.4. By Sales Channel
   13.11. Middle East & Africa Hypoactive Sexual Desire Disorder (HSDD) Treatment Demand Share, 2019-2026

14. Competition Landscape
   14.1. Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market: Market Share Analysis
   14.2. Hypoactive Sexual Desire Disorder (HSDD) Treatment Distributors and Customers
   14.3. Hypoactive Sexual Desire Disorder (HSDD) Treatment Market: Competitive Dashboard
   14.4. Company Profiles (Details  Overview, Financials, Developments, Strategy) 
      14.4.1. AMAG Pharmaceuticals
         14.4.1.1. Overview
         14.4.1.2. Financials
         14.4.1.3. Developments
         14.4.1.4. Strategic Outlook
      14.4.2. Allergan, Plc.
         14.4.2.1. Overview
         14.4.2.2. Financials
         14.4.2.3. Developments
         14.4.2.4. Strategic Outlook
      14.4.3. Ivix LLX
         14.4.3.1. Overview
         14.4.3.2. Financials
         14.4.3.3. Developments
         14.4.3.4. Strategic Outlook
      14.4.4. EndoCeutics, Inc.
         14.4.4.1. Overview
         14.4.4.2. Financials
         14.4.4.3. Developments
         14.4.4.4. Strategic Outlook
      14.4.5. Emotional Brain BV
         14.4.5.1. Overview
         14.4.5.2. Financials
         14.4.5.3. Developments
         14.4.5.4. Strategic Outlook
      14.4.6. S1 Biopharma, Inc.
         14.4.6.1. Overview
         14.4.6.2. Financials
         14.4.6.3. Developments
         14.4.6.4. Strategic Outlook
      14.4.7. Sprout Pharmaceuticals, Inc.
         14.4.7.1. Overview
         14.4.7.2. Financials
         14.4.7.3. Developments
         14.4.7.4. Strategic Outlook
      14.4.8. Hypoactive Sexual Desire Disorder (HSDD) Treatmen
         14.4.8.1. Overview
         14.4.8.2. Financials
         14.4.8.3. Developments
         14.4.8.4. Strategic Outlook
      14.4.9. COMPANY9
         14.4.9.1. Overview
         14.4.9.2. Financials
         14.4.9.3. Developments
         14.4.9.4. Strategic Outlook
      14.4.10. COMPANY 10
         14.4.10.1. Overview
         14.4.10.2. Financials
         14.4.10.3. Developments
         14.4.10.4. Strategic Outlook
      14.4.11. COMPANY 11
         14.4.11.1. Overview
         14.4.11.2. Financials
         14.4.11.3. Developments
         14.4.11.4. Strategic Outlook
      14.4.12. COMPANY 12
         14.4.12.1. Overview
         14.4.12.2. Financials
         14.4.12.3. Developments
         14.4.12.4. Strategic Outlook
      14.4.13. COMPANY 13
         14.4.13.1. Overview
         14.4.13.2. Financials
         14.4.13.3. Developments
         14.4.13.4. Strategic Outlook
      14.4.14. COMPANY 14
         14.4.14.1. Overview
         14.4.14.2. Financials
         14.4.14.3. Developments
         14.4.14.4. Strategic Outlook
      14.4.15. COMPANY 15
         14.4.15.1. Overview
         14.4.15.2. Financials
         14.4.15.3. Developments
         14.4.15.4. Strategic Outlook
      14.4.16. COMPANY 16
         14.4.16.1. Overview
         14.4.16.2. Financials
         14.4.16.3. Developments
         14.4.16.4. Strategic Outlook
      14.4.17. COMPANY 17
         14.4.17.1. Overview
         14.4.17.2. Financials
         14.4.17.3. Developments
         14.4.17.4. Strategic Outlook
      14.4.18. COMPANY 18
         14.4.18.1. Overview
         14.4.18.2. Financials
         14.4.18.3. Developments
         14.4.18.4. Strategic Outlook
      14.4.19.&n

Full Name

Work Email

Contact Number

Company Name

Title/Designation

Country

How can we help you?

Report Attributes	Report Details
Report Title	Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Research Report
By Type	Buspirone, Bupropion, Testosterone, Flibanserin, Bremelanotide, Cognitive Behavior Therapy, Hypoactive Sexual Desire Disorder (HSDD) Treatmen
By Application	Hospitals, Clinic, Others
By Companies	AMAG Pharmaceuticals, Allergan, Plc., Ivix LLX, EndoCeutics, Inc., Emotional Brain BV, S1 Biopharma, Inc., Sprout Pharmaceuticals, Inc., Hypoactive Sexual Desire Disorder (HSDD) Treatmen
Regions Covered	North America, Europe, APAC, Latin America, MEA
Base Year	2021
Historical Year	2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year	2030
Number of Pages	245
Number of Tables & Figures	172
Customization Available	Yes, the report can be customized as per your need.

	Single User	$ 3300
	Multi User	$ 4200
	Corporate User	$ 5500

Market Overview:

Product Definition:

Buspirone:

Bupropion:

Application Insights:

Regional Analysis:

Growth Factors:

Scope Of The Report

Global Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Report Segments:

Highlights of The Hypoactive Sexual Desire Disorder (HSDD) Treatment Market Report:

Buspirone

Bupropion

Testosterone

Flibanserin

Bremelanotide

Cognitive Behavior Therapy